Conference will be held Feb. 11-13 at the Waldorf-Astoria Hotel in New York
NEW YORK, Jan. 24 /PRNewswire/ -- Gerson Lehrman Group (GLG) and the Biotechnology Industry Organization (BIO) today announced a collaborative agreement designed to strengthen the access to clinical information and insights at the tenth annual BIO CEO & Investor Conference.
"We're thrilled to have this unique partnership opportunity with BIO in their tireless efforts to increase the relevant and timely dissemination of some of the most highly technical and challenging scientific issues of today," said Alexander Saint-Amand, Chief Executive Officer of GLG. "Our company's long-standing mission is to empower decision-makers by connecting them to the academic and industry leaders driving innovation and productivity in our global economy."
Through this partnership, BIO will tap into GLG's network of experts from around the world in order to identify the most relevant thought leaders to discuss the latest issues and trends affecting drug development and clinical design in the biotechnology industry.
"Gerson Lehrman Group is an ideal partner for BIO's annual investment conferences with deep access to the clinical experts and investigators who can bring insights to pipeline research and current clinical practices," said James C. Greenwood, president and CEO of BIO. "Our Therapeutic Workshops and Business Roundtable discussions focus on educating investors and industry management on the issues that face product innovation, capitalization and commercialization."
The BIO CEO & Investor Conference is the largest independent biotechnology investor conference focused on publicly-traded companies. The conference features issue-oriented plenary sessions, educational sessions on therapeutic areas and business issues, company presentations, one-on-one meetings, and networking opportunities.
To see the latest updates on 200
|SOURCE Gerson Lehrman Group|
Copyright©2008 PR Newswire.
All rights reserved